Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis
Zobair M. Younossi, Maria Stepanova, Quentin M. Anstee, et al.
Clinical Gastroenterology and Hepatology (2019) Vol. 17, Iss. 12, pp. 2552-2560.e10
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai‐Sun Wong, et al.
Hepatology International (2020) Vol. 14, Iss. 6, pp. 889-919
Open Access | Times Cited: 637
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
Zobair M. Younossi, Mary E. Rinella, Arun J. Sanyal, et al.
Hepatology (2020) Vol. 73, Iss. 3, pp. 1194-1198
Closed Access | Times Cited: 360
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
Zobair M. Younossi, Linda Henry
JHEP Reports (2021) Vol. 3, Iss. 4, pp. 100305-100305
Open Access | Times Cited: 160
Management of non-alcoholic fatty liver disease
Maria Letizia Petroni, Lucia Brodosi, Elisabetta Bugianesi, et al.
BMJ (2021), pp. m4747-m4747
Open Access | Times Cited: 147
Cigarette smoking and liver diseases
David Martí‐Aguado, Ana Clemente, Ramón Bataller
Journal of Hepatology (2022) Vol. 77, Iss. 1, pp. 191-205
Open Access | Times Cited: 104
The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019
James M. Paik, Linda Henry, Youssef Younossi, et al.
Hepatology Communications (2023) Vol. 7, Iss. 10
Open Access | Times Cited: 79
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gómez, Salvatore Petta, et al.
Hepatology (2022) Vol. 77, Iss. 4, pp. 1404-1427
Closed Access | Times Cited: 76
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
Zobair M. Younossi, Linda Henry
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 9-19
Open Access | Times Cited: 19
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu, et al.
Hepatology International (2025)
Closed Access | Times Cited: 3
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
Zobair M. Younossi, Quentin M. Anstee, Vincent Wai‐Sun Wong, et al.
Gastroenterology (2020) Vol. 160, Iss. 5, pp. 1608-1619.e13
Closed Access | Times Cited: 81
Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices
Zobair M. Younossi, Kathleen E. Corey, Naim Alkhouri, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 52, Iss. 3, pp. 513-526
Closed Access | Times Cited: 80
A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease
Zobair M. Younossi, Janus P. Ong, Hirokazu Takahashi, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 6, pp. e1456-e1468
Open Access | Times Cited: 79
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
Zobair M. Younossi, Maria Stepanova, Fatema Nader, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 9, pp. 2050-2058.e12
Open Access | Times Cited: 69
The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes
Zobair M. Younossi, Priya Aggarwal, Ichhya Shrestha, et al.
JHEP Reports (2022) Vol. 4, Iss. 9, pp. 100525-100525
Open Access | Times Cited: 68
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
Wayne Eskridge, Donna R. Cryer, Jörn M. Schattenberg, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 19, pp. 6216-6216
Open Access | Times Cited: 32
Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
Pegah Golabi, Soroor Owrangi, Zobair M. Younossi
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Open Access | Times Cited: 13
Changing from NAFLD to MASLD: The implications for health-related quality of life data
Ryuki Hashida, Dan Nakano, Machiko Kawaguchi, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. e249-e251
Closed Access | Times Cited: 11
Assessment of fatigue and its impact in chronic liver disease
Zobair M. Younossi, Andreas E. Kremer, Mark G. Swain, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 726-742
Closed Access | Times Cited: 9
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
Zobair M. Younossi, Homie Razavi, Michael S. Sherman, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review
Lea Ladegaard Grønkjær, Mette Munk Lauridsen
JHEP Reports (2021) Vol. 3, Iss. 6, pp. 100370-100370
Open Access | Times Cited: 51
Nonalcoholic fatty liver disease: lifestyle and quality of life
Ilias D. Vachliotis, A. Goulas, Paraskevi Papaioannidou, et al.
HORMONES (2021) Vol. 21, Iss. 1, pp. 41-49
Closed Access | Times Cited: 41
The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Yasser Fouad, Gamal Esmat, Reda Elwakil, et al.
Saudi Journal of Gastroenterology (2022) Vol. 28, Iss. 1, pp. 3-20
Open Access | Times Cited: 32
Nonalcoholic fatty liver disease and non-liver comorbidities
Richie Manikat, Mindie H. Nguyen
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. Suppl, pp. s86-s102
Open Access | Times Cited: 21
Economic Burden and Patient-Reported Outcomes of Nonalcoholic Fatty Liver Disease
Maria Stepanova, Linda Henry, Zobair M. Younossi
Clinics in Liver Disease (2023) Vol. 27, Iss. 2, pp. 483-513
Closed Access | Times Cited: 17
Review and expert opinion on MAFLD, oxidative stress and multifunctional management
Francesco Angelico, Diana Alcantara‐Payawal, Rafiz Abdul Rani, et al.
Drugs in Context (2024) Vol. 13, pp. 1-11
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top